Coronavirus: Roche requests Anvisa emergency use of remedy against Covid-19

The National Health Surveillance Agency received a request for the emergency use of medicine against Covid-19. The order came from the pharmaceutical company Roche, who sent it last Thursday (1st).

The drug consists of a cocktail, which contains the substances casirivimab and imdevimab. Both are experimental remedies created by American biotechnology specialist Regeneron.

The drug even received authorization on an emergency basis by the FDA – the North American regulatory agency -, as it showed satisfactory results in patients with mild and moderate symptoms of Covid-19.

“In a clinical trial of patients with Covid-19, casirivimab and imdevimab, administered together, were shown to reduce Covid-19-related hospitalization or emergency visits in patients at high risk of disease progression within 28 days after treatment, when compared to placebo. The safety and efficacy of this experimental therapy for use in the treatment of Covid-19 continues to be evaluated. ”


The cocktail is applied intravenously, that is, through a direct injection into the bloodstream. Now, Anvisa will have a period of 30 days to assess whether it can approve the emergency use of the drug in Brazil. The agency will use the FDA report as a basis for the opinion.

You can access the latest news about the new coronavirus pandemic on our special page dedicated to the subject. Access is available through this link.

What are your expectations for the request sent by Roche to Anvisa? Tell us in the space for comments.


Get the latest news delivered to your inbox

Follow us on social media networks

PREV three SC journalists die from Covid-19
NEXT PBH Committee meets on Wednesday to assess Covid-19 pandemic